Short Interest in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Grows By 27.9%

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) was the target of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 3,281 shares, an increase of 27.9% from the January 15th total of 2,565 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average daily volume of 10,160 shares, the short-interest ratio is presently 0.3 days. Based on an average daily volume of 10,160 shares, the short-interest ratio is presently 0.3 days. Currently, 0.1% of the company’s shares are short sold.

Institutional Investors Weigh In On Invesco Biotechnology & Genome ETF

Large investors have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. raised its holdings in Invesco Biotechnology & Genome ETF by 9,169.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 342,971 shares of the company’s stock worth $28,175,000 after buying an additional 339,271 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management grew its holdings in Invesco Biotechnology & Genome ETF by 4.2% during the second quarter. Gerber Kawasaki Wealth & Investment Management now owns 254,172 shares of the company’s stock worth $16,292,000 after buying an additional 10,213 shares in the last quarter. LPL Financial LLC raised its position in Invesco Biotechnology & Genome ETF by 5.0% in the 4th quarter. LPL Financial LLC now owns 97,304 shares of the company’s stock valued at $7,994,000 after buying an additional 4,617 shares during the last quarter. United Capital Financial Advisors LLC purchased a new stake in Invesco Biotechnology & Genome ETF in the 3rd quarter valued at $5,946,000. Finally, Royal Bank of Canada boosted its holdings in Invesco Biotechnology & Genome ETF by 22.3% during the 1st quarter. Royal Bank of Canada now owns 75,402 shares of the company’s stock worth $4,783,000 after acquiring an additional 13,767 shares during the last quarter.

Invesco Biotechnology & Genome ETF Stock Performance

Shares of PBE stock traded up $0.74 on Monday, hitting $81.55. The company had a trading volume of 3,730 shares, compared to its average volume of 7,301. Invesco Biotechnology & Genome ETF has a twelve month low of $54.52 and a twelve month high of $85.73. The firm has a market cap of $261.78 million, a P/E ratio of 20.44 and a beta of 0.79. The stock’s 50-day moving average is $82.30 and its two-hundred day moving average is $75.88.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.